Hyperuricemia Treatment Market 2032: Clinical Trials, EMA, PDMA, FDA Approvals, Epidemiology, Therapies, Companies by DelveInsight

Hyperuricemia companies are LG Chem, Shanton Pharma, InventisBio Co., Ltd, Jiangsu HengRui Medicine Co., Ltd., Fuji Yakuhin Co., Ltd., Virchow Group, Sanofi, Kissei Pharmaceutical Co., Ltd, Getz Pharma, Ardea Biosciences, Inc., Urica Therapeutics Inc., Nuon Therapeutics, Inc., CymaBay Therapeutics, Inc., JW Pharmaceutical, Selecta Biosciences, Inc., and others.
(Albany, US) DelveInsight's "Hyperuricemia - Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hyperuricemia, historical and forecasted epidemiology as well as the Hyperuricemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Request for sample report @ Hyperuricemia Treatment Market [https://www.delveinsight.com/report-store/hyperuricemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Some facts of the Hyperuricemia Market Report are:

* According to DelveInsight, Hyperuricemia market is expected to grow at a decent CAGR during the forecast period.
* Hyperuricemia companies working in the treatment market are LG Chem, Shanton Pharma, InventisBio Co., Ltd, Jiangsu HengRui Medicine Co., Ltd., Fuji Yakuhin Co., Ltd., Virchow Group, Sanofi, Kissei Pharmaceutical Co., Ltd, Getz Pharma, Ardea Biosciences, Inc., Urica Therapeutics Inc., Nuon Therapeutics, Inc., CymaBay Therapeutics, Inc., JW Pharmaceutical, Selecta Biosciences, Inc., and others, are developing therapies for the Hyperuricemia treatment.
* Emerging Hyperuricemia therapies in the different phases of clinical trials are - Tigulixostat(LC350189), SAP-001, D-0120, SHR4640, FYU-981, TULY, Rasburicase, KUX-1151, Febuxostat, RDEA594, RDEA806, dontinurad, Tranilast, Arhalofenate, URC102, SEL-212, and others are expected to have a significant impact on the Hyperuricemia market in the coming years.
* The most recent significant study of hyperuricemia and gout found that 43.3 million Americans have the condition.
* The prevalence rate of hyperuricemia in the general population is estimated at 20-25%, but only 4-6% in premenopausal women
* The prevalence of gout is 5.9% in men and 2% in women.
* In June 2022, Scilex Holding Company, a nearly 100% majority-owned subsidiary of Sorrento Therapeutics, Inc., a commercial biopharmaceutical company focused on developing and manufacturing, and distributing non-opioid therapies for patients suffering from acute and chronic pain, entered into a license and commercialization agreement with RxOmeg Therapeutics LLC for the exclusive right to market and distribute in the U.S. Gloperba is an oral gout medication for adults.
* In November 2021, Allena Pharmaceuticals, Inc., which is a late-stage biopharmaceutical company using its novel oral biologic platform to discover, develop, and commercialize first-in-class oral Enzyme therapeutics for difficult-to-treat metabolic diseases, announced that its orally-administered, urate-degrading enzyme, ALLN-346, has received FDA Fast Track designation. ALLN-346 is now in Phase 2 testing for the treatment of hyperuricemia in gout patients with severe CKD.

Request for sample report to know more about Hyperuricemia epidemiology trends @ Hyperuricemia Prevalence [https://www.delveinsight.com/sample-request/hyperuricemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Scope of the Hyperuricemia Market Report

* The Hyperuricemia market report covers the descriptive overview of Hyperuricemia, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
* Comprehensive insight has been provided into the Hyperuricemia epidemiology and treatment in the 7MM
* Additionally, an all-inclusive account of both the current and emerging therapies for Hyperuricemia are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
* A detailed review of Hyperuricemia market; historical and forecasted is included in the report, covering drug outreach in the 7MM
* The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Hyperuricemia market

Request for sample report @ Hyperuricemia Market Forecast [https://www.delveinsight.com/report-store/hyperuricemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Hyperuricemia Overview:

Hyperuricemia occurs when there's too much uric acid in your blood. High uric acid levels can lead to several diseases, including a painful type of arthritis called gout. Elevated uric acid levels are also associated with health conditions such as heart disease, diabetes, and kidney disease.

Uric acid is formed when purines break down in your body. Purines are chemicals found in certain foods. This typically includes:

* red meat
* organ meat
* seafood
* beans

Normally, your body rids itself of uric acid when you urinate. Hyperuricemia occurs when your body either makes too much uric acid or is unable to excrete enough of it. It usually happens because your kidneys aren't eliminating it quickly enough.

Excess uric acid levels in your blood can lead to the formation of crystals. Although these can form anywhere in the body, they tend to form in and around your joints and in your kidneys. Your body's defensive white blood cells may attack the crystals, causing inflammation and pain.

Rates of hyperuricemia have risen sharply since 1960.

Hyperuricemia Treatment Market

Therapeutic strategies used to treat hyperuricemia are often focused on limiting acute episodes characterized by an inflammatory response of cells triggered by urate crystal deposition. These events are counteracted using NSAIDs, colchicine, or glucocorticoids which act through different mechanisms. NSAIDs' effect is due to the inhibition of prostaglandin generation by up-regulated COX-2, recognized as the most important event in the stimulation of inflammatory responses which characterize gouty arthritis attacks. Further, in vitro studies have shown that high concentrations of colchicine suppress inflammation by blocking IL-1 beta processing in monocytes stimulated by monosodium urate (MSU).

Moreover, it downregulates tyrosine kinases and phospholipases in neutrophils, inhibiting chemotaxis, superoxide anion production, adhesion to cellular substrata, and mobilization and release of lysosomal enzymes during phagocytosis. Currently, the drugs of first choice for long-term management of hyperuricemia are XO inhibitors with uricostatic features (eg, allopurinol, oxypurinol, febuxostat), which lower serum uric acid (SUA) levels through competitive inhibition of XO. Following oral administration, allopurinol is rapidly absorbed in the upper gastrointestinal tract, reaching peak plasma concentrations in approximately 30 minutes, and it has a plasma half-life of 2-3 hours. The main active metabolite of allopurinol is oxypurinol, excreted and partly reabsorbed in the kidneys; it has the same mechanism of action, a longer plasma half-life of 14-30 hours, but lower oral bioavailability than its precursor.

Febuxostat is a new non purine, selective inhibitor of XO, that blocks the active pterin-molybdenum center of the enzyme complex, and unlike allo/oxypurinol, does not determine enzyme turnover, avoiding the consequent undesired production of ROS. Following oral administration, it is completely absorbed in the upper gastrointestinal tract, reaching peak plasma concentrations in approximately 1 hour, with a plasma half-life of 1.5-16 hours It is metabolized and excreted predominantly through hepatic conjugation processes. The standard dosage of febuxostat is 80-120 mg/day, even though remarkable decreases in SUA levels have been observed with a lower dose of 40 mg/day. Takeda's ULORIC (febuxostat), is a xanthine oxidase (XO) inhibitor indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable.

Click here to know in detail about the Hyperuricemia Market Drivers, Barriers and Trends @ Hyperuricemia Market Dynamics [https://www.delveinsight.com/sample-request/hyperuricemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

The major players covered in the hyperuricemia drugs market are:

* Takeda Pharmaceutical Company Limited
* Mylan N.V.
* Sun Pharmaceutical Industries Limited
* Hikma Pharmaceutical PLC
* Dr. Reddy's Laboratories Ltd
* Sanofi
* Sandoz AG
* Amneal Pharmaceuticals LLC
* And Many Others

Request for sample report @ Hyperuricemia Clinical Trials [https://www.delveinsight.com/sample-request/hyperuricemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Table of Contents:

1. Key Insights

2. Executive Summary of Hyperuricemia

3. Competitive Intelligence Analysis for Hyperuricemia

4. Hyperuricemia: Market Overview at a Glance

5. Hyperuricemia: Disease Background and Overview

6. Patient Journey

7. Hyperuricemia Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Hyperuricemia Treatment

11. Marketed Products

12. Emerging Therapies

13. Hyperuricemia: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Hyperuricemia

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hyperuricemia-treatment-market-2032-clinical-trials-ema-pdma-fda-approvals-epidemiology-therapies-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting



This release was published on openPR.